Navigating the NASH Maze
The availability of 2 approved medicines for the treatment of idiopathic pulmonary fibrosis (IPF) has stimulated an explosion in fibrosis research and in the search for new anti-fibrotic agents. Nowhere is this more evident than in the field of non-alcoholic steatohepatitis (NASH). While there have been multiple review articles covering NASH of late, TherapeutAix is […]